ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1779

Is the Number of IgG4+ Plasma Cells Observed By Immunostaining Important Beyond Its Diagnostic Utility in IgG4-Related Disease?

Eduardo Martín Nares1, Jacobo Guerrero Castillo2, Arturo Angeles Angeles2 and Gabriela Hernandez-Molina1, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Department of Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: biopsies, IgG4 Related Disease, nephritis and plasma cells, Retroperitoneal Fibrosing

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The histopathological findings in IgG4-related disease (IgG4-RD) includes the presence of dense lymphoplasmacytic infiltrate, obliterative phlebitis, storiform fibrosis and the presence of marked IgG4+ plasma cell infiltration observed by immunostaining. The latter has been used in clinical practice only as a diagnostic tool. Whether the number of IgG4+ plasma cells in tissue is associated with any clinical or serological feature has not been previously evaluated. The purpose of this study was to evaluate if the grade of IgG4+ plasma cell infiltration is associated with any clinical or serological outcome.

Methods: We included patients with biopsy proven IgG4-RD according to the Comprehensive Diagnostic Criteria (definitive and probable IgG4-RD) who regularly attended a tertiary referral center in Mexico City (2000-2017). We collected demographics, clinical (organ involvement, relapses and the disease activity assessed by the IgG4-RD Responder Index [IgG4-RD RI] at baseline) as well as baseline laboratory data (C3, C4, total eosinophil count, IgG4 levels). Patients were divided in three groups according to the number of IgG4+ plasma cells in biopsies as follows: <50 IgG4+ plasma cells/HPF, 50-100 IgG4+ plasma cells/HPF, and >100 IgG4+ plasma cells/HPF.

Results:

We included 30 patients, 17 (56.6%) women, mean age 53 ± 13.9 years and median disease duration 13 months. The biopsies were from the following tissues: lacrimal gland (n=6), pancreas (n=5), orbit (n=4), kidney (n=4), lymph node (n=3), mediastinum (n=2), salivary gland (n=2) and other tissues (n=4). Eleven patients (36.6%) had <50 IgG4+ plasma cells/HPF, 9 patients (30%) 50-100 IgG4+ plasma cells/HPF and 10 (33.3%) patients >100 IgG4+ plasma cells/HPF. We did not find any difference regarding age, gender, time of follow up, number of involved organs and relapses. The median baseline IgG4-RD RI was 9, 6 and 15, for the <50 IgG4+ plasma cells/HPF, 50-100 IgG4+ plasma cells/HPF, and >100 IgG4+ plasma cells/HPF groups respectively, however, there was not a statistical difference. The group with >100 IgG4+ plasma cells/HPF had more frequently lymphadenopathy when compared with the other groups (36.4%, 66.7% and 80%, p=0.02; respectively) while the proportion of involvement of the remaining anatomic sites were similar. We found a statistical difference in serum C3 levels (99.5 mg/dl, 159 mg/dl, 78.5 mg/dl, p=0.04) and a tendency for serum C4 levels (20 mg/dl, 27 mg/dl, and 6 mg/dl, p=0.08) among the groups with >100 and ≤ 100 IgG4+ plasma cells/HPF, respectively; whereas the levels of serum IgG4 and the eosinophil count were similar. The C3 and C4 serum levels negatively correlated with the basal IgG4-RD RI (t=-0.48, p=0.005 and t=-0.58, p=0.001).

Conclusion: Our results show that the number of IgG4+ plasma cells observed by immunostaining in IgG4-RD may be of value in identifying a subset of patients with hypocomplementemia, lymphadenopathy and higher baseline disease activity. The finding of an association between hypocomplementemia and higher tissue infiltration by IgG4+ plasma cells expands the evidence that complement activation may contribute to the pathogenesis of IgG4-RD.


Disclosure: E. Martín Nares, None; J. Guerrero Castillo, None; A. Angeles Angeles, None; G. Hernandez-Molina, None.

To cite this abstract in AMA style:

Martín Nares E, Guerrero Castillo J, Angeles Angeles A, Hernandez-Molina G. Is the Number of IgG4+ Plasma Cells Observed By Immunostaining Important Beyond Its Diagnostic Utility in IgG4-Related Disease? [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/is-the-number-of-igg4-plasma-cells-observed-by-immunostaining-important-beyond-its-diagnostic-utility-in-igg4-related-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-the-number-of-igg4-plasma-cells-observed-by-immunostaining-important-beyond-its-diagnostic-utility-in-igg4-related-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology